Zim Laboratories profit and loss

Latest FY26

Revenue: ₹374cr−1.2% on FY25
EBITDA: ₹30.0cr−31.4% on FY25
Net profit: ₹5.8cr−52.0% on FY25
EPS: ₹1.19−52.4% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023

Expenses
	397	374	379	367	399
	10.9	11.4	5.8	5.2	6.4
	408	386	385	373	405
	180	164	155	178	165
	6.4	7.5	11.6	7.8	17.4
	−11.8	−6.1	1.3	−14.1	16.5
	68.5	63.9	60.8	53.3	49.3
	13.5	13.2	11.4	6.9	5.6
	20.5	20.0	20.1	16.0	17.5
	125	115	107	101	98.4
	403	378	367	349	370
	28.2	30.0	43.7	41.3	52.0
	7.7	10.0	23.6	25.4	34.5
Profit
	5.1	8.2	18.0	23.6	35.4
	5.1	8.2	18.0	23.6	35.4
	3.3	3.4	4.7	0.9	6.3
	−2.0	−1.0	1.2	5.5	4.6
	1.4	2.4	5.8	6.4	10.9
	3.7	5.8	12.2	17.2	24.4
	3.7	5.8	12.2	17.2	24.4
	2.1	2.1	−0.0	−0.2	0.7
	5.8	7.9	12.1	17.0	25.1
	3.7	5.8	12.2	17.2	24.4
	−0.0	0.0	−0.0	−0.0	0.0
Per share
	₹0.82	₹1.19	₹2.50	₹3.54	₹5.01
	₹0.82	₹1.19	₹2.50	₹3.54	₹5.01
Other comprehensive income — detail
	2.1	2.1	−0.0	—	—
	0.0	−0.1	−0.8	−0.5	−0.7
	0.0	−0.0	−0.2	—	—
	—	—	—	−0.2	−0.2
	2.0	2.2	0.5	0.1	1.1
	6.2	7.9	12.1	17.0	25.1
	−0.1	0.0	−0.0	−0.0	0.0
Per share — as-filed variants
	₹0.82	₹1.19	₹2.50	₹3.54	₹5.01
	₹0.82	₹1.19	₹2.50	₹3.54	₹5.01
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	222	209	211	196	200
	55.9%	55.8%	55.7%	53.3%	50.1%
Adjusted (ex-exceptional items) — derived
	5.1	8.2	18.0	23.6	35.4
	3.7	5.8	12.2	17.2	24.4
	₹0.82	₹1.19	₹2.50	₹3.54	₹5.01

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ZIMLAB₹141.26

Zim Laboratories Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersANUHPHR VALIANTLAB AHCL ALBERTDAVD WANBURY HALEOSLABS BAJAJHCARE THEMISMEDMcap ₹756 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	398.5	367.4	379.0	374.4	396.8
Other Income	6.4	5.2	5.8	11.4	10.9
Total Income	404.9	372.6	384.8	385.8	407.7
Expenses
+ Cost of Materials Consumed	165.0	177.7	155.0	164.0	180.2
+ Purchases of Stock-in-Trade	17.4	7.8	11.6	7.5	6.4
+ Changes in Inventories	16.5	-14.1	1.3	-6.1	-11.8
+ Employee Benefit Expense	49.3	53.3	60.8	63.9	68.5
+ Finance Costs	5.6	6.9	11.4	13.2	13.5
+ Depreciation & Amortisation	17.5	16.0	20.1	20.0	20.5
+ Other Expenses	98.4	101.3	106.7	115.1	125.3
Total Expenses	369.6	349.0	366.8	377.6	402.6
EBITDA	52.0	41.3	43.7	30.0	28.2
EBIT	34.5	25.4	23.6	10.0	7.7
Profit
PBT before Exceptional Items	35.4	23.6	18.0	8.2	5.1
Pretax Income	35.4	23.6	18.0	8.2	5.1
+ Current Tax	6.3	0.9	4.7	3.4	3.3
+ Deferred Tax	4.6	5.5	1.2	-1.0	-2.0
Tax Expense	10.9	6.4	5.8	2.4	1.4
Net Income	24.4	17.2	12.2	5.8	3.7
+ Net Income — Continuing Ops	24.4	17.2	12.2	5.8	3.7
+ Other Comprehensive Income	0.7	-0.2	-0.0	2.1	2.1
Total Comprehensive Income	25.1	17.0	12.1	7.9	5.8
Net Income to Common	24.4	17.2	12.2	5.8	3.7
Minority Interest	0.0	-0.0	-0.0	0.0	-0.0
Per Share
Basic EPS	5.01	3.54	2.50	1.19	0.82
Diluted EPS	5.01	3.54	2.50	1.19	0.82
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-0.0	2.1	2.1
+ Items NOT to be Reclassified to P&L	-0.7	-0.5	-0.8	-0.1	0.0
+ Tax on Items NOT to be Reclassified	—	—	-0.2	-0.0	0.0
+ Tax on Items NOT to be Reclassified — alt tag	-0.2	-0.2	—	—	—
+ Items to be Reclassified to P&L	1.1	0.1	0.5	2.2	2.0
Comprehensive Income — Owners of Parent	25.1	17.0	12.1	7.9	6.2
Comprehensive Income — Non-controlling Interests	0.0	-0.0	-0.0	0.0	-0.1
Per Share — as-filed variants
Basic EPS — Continuing Operations	5.01	3.54	2.50	1.19	0.82
Diluted EPS — Continuing Operations	5.01	3.54	2.50	1.19	0.82
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	199.7	196.0	211.2	209.0	222.0
Gross Margin %	50.11	53.34	55.72	55.83	55.94
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	35.4	23.6	18.0	8.2	5.1
Net Income Adj (tax-effected)	24.4	17.2	12.2	5.8	3.7
EPS Adj	5.01	3.54	2.50	1.19	0.82
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Filed Debt Equity	0.00	0.00	0.44	0.42	0.50
Filed Dscr	2.00	2.00	1.65	1.13	0.53
Filed Iscr	7.00	4.00	2.58	1.62	-0.53
Paid Up Equity Capital	48.7	48.7	48.7	53.5	53.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.